Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)

Transfemoral versus transcarotid access for transcatheter aortic valve replacement




Julkaisun tekijätOlivier Maud-Emmanuelle, Di Cesare Alessandro, Poncet Anne, Brasselet Camille, Metz Damien, Biancari Fausto, Ruggieri Vito Giovanni, The Reims Heart Team Group

KustantajaElsevier Inc.

Julkaisuvuosi2022

JournalJTCVS Techniques

Tietokannassa oleva lehden nimiJTCVS Techniques

Volyymi15

Aloitussivu46

Lopetussivun numero53

DOIhttp://dx.doi.org/10.1016/j.xjtc.2022.05.019

Verkko-osoitehttps://doi.org/10.1016/j.xjtc.2022.05.019

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/176604281


Tiivistelmä

Objectives: To compare the outcomes after transcatheter aortic valve replacement (TAVR) through a transfemoral (TF) and transcarotid (TC) access at our institution.

Methods: From January 2014 to January 2020, 62 TC-TAVR and 449 TF-TAVR were performed using 2 prosthesis devices (Edwards SAPIEN 3, n = 369; Medtronic Evolut R, n = 142). Propensity score matching was used to adjust for imbalance in the baseline characteristics of the study groups.

Results: Propensity score matching provided 62 matched pairs with comparable operative risk (mean European System for Cardiac Operative Risk Evaluation II, TC-TAVR 7.6% vs TF-TAVR 6.6%, P = .17). Thirty-day mortality (4.8% vs 3.2%, P = 1.00) and 2-year mortality (11.3% vs 12.9%, P = .64) after TC-TAVR were comparable with TF-TAVR. Strokes were numerically more frequent after TC-TAVR compared with TF-TAVR (3.2% vs 0%, P = .23), but the difference did not reach statistical significance. TF-TAVR was associated with a significantly greater risk of permanent pacemaker implantation (29.0% vs 12.9%, P = .04) compared with TC-TAVR. Other complications were not frequent and were similarly distributed between the matched groups.

Conclusions: TC access for TAVR was associated with satisfactory results compared to the femoral access. TC-TAVR could be considered a valid and safe alternative to TF-TAVR when femoral access is contraindicated. © 2022


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2023-15-06 at 16:16